OnCo

Sign in to keep your watchlist

Your watched pages live in this browser. Sign in with an email link and OnCo keeps the same list on every device you use. Only your email address and your watchlist are stored.

Erdheim-Chester disease: the decisions you may face

5 treatment settings, 5 with more than one named option. Each section lays out the options the standard of care names, what each is for, the trials behind them with their recorded results, the side effects and cautions on record, and questions to ask. Built from the cancer page's standard-of-care rows; nothing here is advice for your case.

Biopsy of an accessible lesion with BRAF V600E testing and broader sequencing; FDG-PET/CT, cardiac and brain MRI, endocrine assessment.

The options, in plain words

Sequencing hundreds of cancer genes at once from a biopsy to find the mutations a drug can target.

  • One test, all actionable alterations
  • Trial matching
FDG PETStandard of care

FDG PET is the standard PET scan. A radioactive sugar shows which tissues are burning glucose fast, which most cancers do.

  • Universal availability
  • Decades of validation
MRIStandard of care

MRI uses a strong magnet and radio waves, with no ionising radiation, to picture soft tissue in finer contrast than CT, so it is the standard scan for brain tumours, prostate, rectal cancer staging, liver lesions and breast screening in high-risk women. It is slow, expensive and blurred by movement.

  • No ionising radiation
  • Best soft-tissue and brain imaging
  • Functional sequences (diffusion, perfusion)
Liquid biopsy (ctDNA)Standard of care

A blood test that reads fragments of DNA shed by the tumour, so you can genotype or monitor cancer without a needle in the tumour.

  • Minimally invasive, repeatable
  • Whole-body clonal picture
Also referenced:BRAF V600E mutation
The evidence behind it

No trial record is attached to this row yet. The trials tab lists what is recruiting and the landmark trials for this cancer.

The main trade-offs on record
  • Tissue quantity
  • VUS interpretation
  • 2-3 week turnaround
  • Non-specific: infection and inflammation are also hot
  • Brain background
  • Poor in indolent tumours
  • Slow and expensive
  • Motion artefacts
  • Gadolinium concerns in renal impairment
  • Low shedding in some tumours (brain, early-stage)
  • Clonal haematopoiesis false positives
Questions to ask about this decision
  1. Between Comprehensive genomic profiling, FDG PET, MRI and the other options, which do you recommend for me, and what about my case would make you choose differently?
    Why: Guidelines list several reasonable options; the choice turns on details of your tumour, your health and your priorities.
  2. What is each option trying to achieve: cure, long control, or relief of symptoms, and over what time?
    Why: The aim shapes how much side effect and disruption is worth accepting.
  3. What happens if I delay, or decline this step for now? Is the decision reversible?
    Why: Some decisions can wait for a second opinion or a trial slot; others cannot. Knowing which is part of the choice.
  4. Does your recommendation follow the current guideline (Consensus recommendations for Erdheim-Chester disease (Blood 2020)), and if it departs from it, why?
    Why: Departures from guidelines are sometimes right for an individual; they should be explained.
  5. For my situation (diagnosis), which of the standard options do you recommend and why?
    Why: Guideline options include: Biopsy of an accessible lesion with BRAF V600E testing and broader sequencing; FDG-PET/CT, cardiac and brain MRI, endocrine assessment.

Add these to your appointment list, or take the full question set for this cancer.

Other settings

BRAF V600E-mutant symptomatic disease

Vemurafenib (approved 2017) or dabrafenib with trametinib; cobimetinib as an alternative; dose reduction to limit toxicity, treatment continued long term.

The options, in plain words

Vemurafenib was the first BRAF inhibitor (2011); it shrank melanomas in weeks and proved that a single mutation could be drugged in a solid tumour.

Dabrafenib plus trametinib is the BRAF-plus-MEK pill combination, approved for BRAF V600E lung cancer and, since 2022, for any solid tumour with that mutation.

Cobimetinib is the MEK partner for vemurafenib, and the first drug approved for histiocytic neoplasms.

Pills that block the specific enzyme a cancer relies on. Imatinib in 2001 proved a cancer could be switched off by design.

  • Oral, outpatient
  • Dramatic responses in oncogene-addicted cancers
Also referenced:BRAF
The evidence behind it

No trial record is attached to this row yet. The trials tab lists what is recruiting and the landmark trials for this cancer.

The main trade-offs on record
Side effectAny gradeGrade 3+
Arthralgia53%-
Photosensitivity33%-
Cutaneous squamous cell carcinoma / keratoacanthoma · BRIM-3 vemurafenib arm24%-
  • Severe photosensitivity: sun protection.
  • Known QT prolongation. Avoid other QT-prolonging drugs where possible; check ECG and correct potassium and magnesium before and during treatment.

Rates from the label or pivotal trial as recorded on the product page; each grade 3+ figure links to its source.

  • Dabrafenib: take on an empty stomach. Trametinib: take on an empty stomach; both cause pyrexia.
  • Near-universal resistance in metastatic disease
  • Off-target toxicities
Questions to ask about this decision
  1. Between Vemurafenib, Dabrafenib + trametinib, Cobimetinib and the other options, which do you recommend for me, and what about my case would make you choose differently?
    Why: Guidelines list several reasonable options; the choice turns on details of your tumour, your health and your priorities.
  2. What is each option trying to achieve: cure, long control, or relief of symptoms, and over what time?
    Why: The aim shapes how much side effect and disruption is worth accepting.
  3. Which side effects of Vemurafenib are most likely for me, which are reversible, and which would make us stop?
    Why: The recorded rates below come from labels and trials; your own risk depends on dose, other medicines and your health.
  4. What happens if I delay, or decline this step for now? Is the decision reversible?
    Why: Some decisions can wait for a second opinion or a trial slot; others cannot. Knowing which is part of the choice.
  5. Does your recommendation follow the current guideline (Consensus recommendations for Erdheim-Chester disease (Blood 2020)), and if it departs from it, why?
    Why: Departures from guidelines are sometimes right for an individual; they should be explained.
  6. For my situation (braf v600e-mutant symptomatic disease), which of the standard options do you recommend and why?
    Why: Guideline options include: Vemurafenib (approved 2017) or dabrafenib with trametinib; cobimetinib as an alternative; dose reduction to limit toxicity, treatment continued long term.
  7. Am I a candidate for Vemurafenib, Dabrafenib + trametinib, Cobimetinib, and what side effects should I expect?
    Why: Knowing the expected toxicities helps you plan work, family, and supportive care.

Add these to your appointment list, or take the full question set for this cancer.

Other settings

BRAF wild-type symptomatic disease

2 options

Cobimetinib (approved 2022 for histiocytic neoplasms); trametinib as an alternative MEK inhibitor.

The options, in plain words

Cobimetinib is the MEK partner for vemurafenib, and the first drug approved for histiocytic neoplasms.

Pills that block the specific enzyme a cancer relies on. Imatinib in 2001 proved a cancer could be switched off by design.

  • Oral, outpatient
  • Dramatic responses in oncogene-addicted cancers
The evidence behind it

No trial record is attached to this row yet. The trials tab lists what is recruiting and the landmark trials for this cancer.

The main trade-offs on record
  • Near-universal resistance in metastatic disease
  • Off-target toxicities
Questions to ask about this decision
  1. Between Cobimetinib and Small-molecule kinase inhibitors, which do you recommend for me, and what about my case would make you choose differently?
    Why: Guidelines list several reasonable options; the choice turns on details of your tumour, your health and your priorities.
  2. What is each option trying to achieve: cure, long control, or relief of symptoms, and over what time?
    Why: The aim shapes how much side effect and disruption is worth accepting.
  3. What happens if I delay, or decline this step for now? Is the decision reversible?
    Why: Some decisions can wait for a second opinion or a trial slot; others cannot. Knowing which is part of the choice.
  4. Does your recommendation follow the current guideline (Consensus recommendations for Erdheim-Chester disease (Blood 2020)), and if it departs from it, why?
    Why: Departures from guidelines are sometimes right for an individual; they should be explained.
  5. For my situation (braf wild-type symptomatic disease), which of the standard options do you recommend and why?
    Why: Guideline options include: Cobimetinib (approved 2022 for histiocytic neoplasms); trametinib as an alternative MEK inhibitor.
  6. Am I a candidate for Cobimetinib, and what side effects should I expect?
    Why: Knowing the expected toxicities helps you plan work, family, and supportive care.

Add these to your appointment list, or take the full question set for this cancer.

Second line

Second-choice or intolerant

Interferon alfa or pegylated interferon, anakinra, cladribine, methotrexate.

The options, in plain words

Interferon alfa was the first biologic cancer drug (1986). It treated hairy cell leukaemia, CML, melanoma, kidney cancer and Kaposi sarcoma, and has been replaced almost everywhere by better-tolerated agents.

A one-week infusion that puts most people with hairy cell leukaemia into remission for years; also used in multiple sclerosis in tablet form.

The 1948 antifolate that produced the first chemotherapy remissions in childhood leukaemia and the first cure of a solid tumour; still essential in ALL, lymphoma, osteosarcoma and CNS lymphoma.

The evidence behind it

No trial record is attached to this row yet. The trials tab lists what is recruiting and the landmark trials for this cancer.

The main trade-offs on record
  • High-dose methotrexate requires normal renal function, hydration, urine alkalinisation and leucovorin rescue with level monitoring.
Questions to ask about this decision
  1. Between Interferon alfa-2a/2b, Cladribine and Methotrexate, which do you recommend for me, and what about my case would make you choose differently?
    Why: Guidelines list several reasonable options; the choice turns on details of your tumour, your health and your priorities.
  2. What is each option trying to achieve: cure, long control, or relief of symptoms, and over what time?
    Why: The aim shapes how much side effect and disruption is worth accepting.
  3. What happens if I delay, or decline this step for now? Is the decision reversible?
    Why: Some decisions can wait for a second opinion or a trial slot; others cannot. Knowing which is part of the choice.
  4. Does your recommendation follow the current guideline (Consensus recommendations for Erdheim-Chester disease (Blood 2020)), and if it departs from it, why?
    Why: Departures from guidelines are sometimes right for an individual; they should be explained.
  5. For my situation (second-choice or intolerant), which of the standard options do you recommend and why?
    Why: Guideline options include: Interferon alfa or pegylated interferon, anakinra, cladribine, methotrexate.
  6. Am I a candidate for Interferon alfa-2a/2b, Cladribine, Methotrexate, and what side effects should I expect?
    Why: Knowing the expected toxicities helps you plan work, family, and supportive care.

Add these to your appointment list, or take the full question set for this cancer.

Other settings

Asymptomatic bone-limited disease

2 options

Observation with periodic PET and organ screening.

The options, in plain words
FDG PETStandard of care

FDG PET is the standard PET scan. A radioactive sugar shows which tissues are burning glucose fast, which most cancers do.

  • Universal availability
  • Decades of validation
Active surveillanceStandard of care

For low-risk prostate cancer, monitoring with PSA, MRI, and repeat biopsy instead of treating, because most such cancers never cause harm.

  • Avoids incontinence and erectile dysfunction of treatment in men who would never be harmed
  • Level-1 evidence of safety (ProtecT)
The evidence behind it

No trial record is attached to this row yet. The trials tab lists what is recruiting and the landmark trials for this cancer.

The main trade-offs on record
  • Non-specific: infection and inflammation are also hot
  • Brain background
  • Poor in indolent tumours
  • Anxiety and adherence
  • Repeat biopsies
  • Under-used outside high-income countries
Questions to ask about this decision
  1. Between FDG PET and Active surveillance, which do you recommend for me, and what about my case would make you choose differently?
    Why: Guidelines list several reasonable options; the choice turns on details of your tumour, your health and your priorities.
  2. What is each option trying to achieve: cure, long control, or relief of symptoms, and over what time?
    Why: The aim shapes how much side effect and disruption is worth accepting.
  3. What happens if I delay, or decline this step for now? Is the decision reversible?
    Why: Some decisions can wait for a second opinion or a trial slot; others cannot. Knowing which is part of the choice.
  4. Does your recommendation follow the current guideline (Consensus recommendations for Erdheim-Chester disease (Blood 2020)), and if it departs from it, why?
    Why: Departures from guidelines are sometimes right for an individual; they should be explained.
  5. For my situation (asymptomatic bone-limited disease), which of the standard options do you recommend and why?
    Why: Guideline options include: Observation with periodic PET and organ screening.

Add these to your appointment list, or take the full question set for this cancer.

How to read this page. Options and results come from OnCo records with their sources; the settings are the standard-of-care rows on the cancer page, and the lines of therapy are on the sequencing grid. Where a setting names one path, the choice is usually about timing, trials and where to be treated: see expert centres. OnCo is orientation, not medical advice.